Himalayas May Not Be Pristine Anymore, Study Shows Presence Of Toxic Metals In Clouds
The study conducted by the Bose Institute, an autonomous body under the Department of Science and Technology (DST), identified significant levels of toxic metals such as cadmium (Cd), copper (Cu), and zinc (Zn) in non-precipitating clouds during the early monsoon season over the Western Ghats and Eastern Himalayas.
For the study, scientists investigated the composition of heavy metals in the non-precipitating low-level clouds collected on the rooftop of the Indian Institute of Tropical Meteorology (IITM) in the Western Ghats and the Bose Institute campus located at Darjeeling in the Eastern Himalayas in 2022.
"Children are at higher risk of 30 per cent of such toxic metals than adults in India. Inhalation of polluted clouds over Eastern Himalayas containing high concentrations of toxic metals is the most potential route for non-carcinogenic diseases," the study published in the journal Science Advances highlighted.
"Health risk for the occurrence of carcinogenic diseases has increased due to inhalation of dissolved Cr present in clouds," it added.
The scientists stated that the inhalation of polluted clouds over the Eastern Himalayas was identified as the main pathway for non-carcinogenic diseases. The study also found that carcinogenic risks have risen due to the inhalation of dissolved chromium present in clouds.
The study linked elevated levels of cadmium, chromium, copper and zinc in the region's clouds to vehicular and industrial emissions from the foothills. They warned that clouds act as transport mediums for heavy metals, which can enter the body through breathing, skin exposure and consumption of rainwater in high-altitude areas.
Despite the alarming findings, the study stated that the Indian clouds remain relatively less polluted compared to countries like China, Pakistan, Italy, and the United States.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 minutes ago
- Time of India
India needs concentrated tooling hubs for advanced manufacturing for aerospace and space domain: S Somanath
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Former Indian Space Research Organisation ( ISRO ) chairman S Somanath on Tuesday said there is an urgent need to develop tooling hubs in India to truly scale advanced manufacturing. He emphasised that India must create focused, concerted manufacturing ecosystems similar to those in at the Accel Advanced Manufacturing Summit in Bengaluru, Somanath said India lacks an ecosystem for aerospace manufacturing. 'Distributed hubs across the country are not a good idea for sectors like aerospace. We need concentrated hubs where all players are aggregated, coupled with institutions that add value to research and innovation,' he highlighted that specialised skills such as tooling are often not addressed in the domain. 'We need people with great knowledge in tooling processes, metallurgy, materials manufacturing, machine tools, process engineering, and automation,' he said, while discussing India's next decade building frontier tech also pointed out that while Indian rockets are witnessing strong global demand, the lack of sufficient supply remains a bottleneck that needs immediate attention. 'Manufacturing becomes the crux of the problem. The ability to manufacture and launch in a short period is essential,' he told startups looking to build in the space sector, highlighting that mass manufacturing in satellites and small launch vehicles will be needed to capture the global startups and deeptech investors also echoed his thoughts and said that for India, space as a defence technology has come much later, and there are areas where it still needs to play Cosmos CEO Srinath Ravichandran said the way to address the gap is not to mimic the SpaceX model but to build from scratch. 'Everyone wants to go build a SpaceX, but that may not be the easiest way to build rockets,' he said, adding that instead of replicating the model, solutions can be built from the Indian context for the Rajaram, managing partner at deeptech venture capital firm Speciale Invest, which has backed several spacetech startups, believes, 'There are certain places we (India) can leapfrog, like in-orbit servicing or any action that you can do in orbit. That's very much a level playing field. Maybe the West is just two or three years ahead of us, and India can compete there.'
Time of India
16 minutes ago
- Time of India
In a year, over 5k women donate to human milk banks in Gujarat
Gandhinagar: As many as 5,537 mothers donated 5,036 litres of milk to human milk banks in the state in 2024-25, providing a new lease of life to 7,829 children, the state govt said on Tuesday. So far, 21,357 women donated milk to human milk banks, and this has benefitted 19,731 newborn children. According to Indian govt guidelines, comprehensive lactation management centres (CLMC) or human milk banks are operational in four medical college hospitals in Surat, Vadodara, Valsad, and Gandhinagar. The human milk bank at Gandhinagar, which was set up in 2021, saw 646 mothers donating milk that benefitted 694 children. So far, 183.18 litres of milk was collected in this bank. The statement said that the SSG Hospital in Vadodara was awarded the NQAS certificate for high-quality standards, making it the first hospital in India to receive such certification. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad About 13 lakh children are born in Gujarat each year, some of whom are preterm or underweight. These children are sensitive in terms of cognitive development and often cannot directly consume their mother's milk due to medical conditions. For these children, milk donated by other mothers becomes life-saving, the statement said. Donated milk can be stored in a deep freezer at -18 to -20 degrees celsius for up to six months, the statement said. The donated milk is pasteurised, rapidly cooled, and sent to the microbiology department for testing. Once the milk is cleared, it is stored in a deep freezer at -18 to -20 degrees celsius. Priority is given to premature babies, those weighing less than 1.8kg, or those admitted to the ICU. The statement said that many mothers produce excess milk even after feeding their child. Such mothers, after feeding their own child, can donate the surplus milk to children who are deprived of their mother's milk for any reason, by depositing it in the bank, the govt said.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
